An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.

Guests

  • Dr. Peter Bach attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.
  • Dr. Carolyn Hendricks a medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA
  • Gardiner Harris science reporter for "The New York Times" and author of the mystery novel 'Hazard.'

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

Friday News Roundup – International

Friday, May 20 2016The latest on the crash of the Egypt Air passenger plane. ISIS ramps up its bombings in Baghdad. And Nigerian authorities say two of the missing schoolgirls captured by Boko Haram have been found. A panel of journalists joins guest host Allison Aubrey for analysis of the week's top international news stories.

Friday News Roundup – Domestic

Friday, May 20 2016Donald Trump unveils his proposed Supreme Court nominees. Bernie Sanders tells the Democratic Party to "let the people in." And the federal government promises action to fight long airport security delays. A panel of journalists joins guest host Allison Aubrey of NPR News for analysis of the week's top national news stories.